[1] ,,Fact Sheets by Cancer [Internet],[cited 2014 Dec,27,-
[2] ,,Breast cancer facts and figures,[cited 2014 Dec,14,-
[3] ,2012,,[cited 2014 Dec,14,202010-
[4] KumarS,BurneyIA,Al-AjmiA,Al-MoundhriMS,,2011,Changing Trends of Breast Cancer Survival in Sultanate of Oman,J Oncol,,316243-
[5] ,,Cancer of the Breast - SEER Stat Fact Sheets,[cited 2014 Dec,14,-
[6] PrimaryBreast,,,Cancer: ESMO Clinical Practice Guidelines | ESMO [Internet],[cited 2014 Dec,14,-
[7] NationalComprehensive Cancer Network,,2015,,[cited 2016 Jan,14,-
[8] LitièreS,WerutskyG,FentimanIS,RutgersE,ChristiaensMR,Van LimbergenE,,2012,Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial,Lancet Oncol,13,412-9
[9] ClarkeM,CollinsR,DarbyS,DaviesC,ElphinstoneP,EvansV,,2005,Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials,Lancet,366,2087-106
[10] GiulianoAE,McCallL,BeitschP,WhitworthPW,BlumencranzP,LeitchAM,,2010,The American College of Surgeons Oncology Group Z0011 randomized trial,Ann Surg,252,426-32
[11] GalimbertiV,ColeBF,ZurridaS,VialeG,LuiniA,VeronesiP,,2013,Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial,Lancet Oncol,14,297-305
[12] DonkerM,van TienhovenG,StraverMF,MeijnenP,van de VeldeCJ,ManselRE,,2014,: a randomised, multicentre, openlabel, phase 3 non-inferiority trial,Lancet Oncol,15,1303-10
[13] KragDN,AndersonSJ,JulianTB,BrownAM,HarlowSP,CostantinoJP,,2010,Sentinel-lymph node resection compared with conventional axillary lymph node dissection in clinically node negative patients with breast cancer. Overall survival findings from the NSABP-B32 randomized phase III trial,Lancet Oncol,11,927-33
[14] BougheyJC,SumanVJ,MittendorfEA,AhrendtGM,WilkeLG,TabackB,,2013,Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial,JAMA,310,1455-61
[15] KuehnT,BauerfeindI,FehmT,FleigeB,HausschildM,HelmsG,,2013,Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study,Lancet Oncol,14,609-18
[16] BearHD,AndersonS,BrownA,SmithR,MamounasEP,FisherB,,2003,,The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 . J Clin Oncol,21,4165-74
[17] MussHB,BerryDA,CirrincioneCT,TheodoulouM,MauerAM,KornblithAB,,2009,Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer,N Engl J Med,360,2055-65
[18] SparanoJA,WangM,MartinoS,JonesV,PerezEA,SaphnerT,,2008,Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer,N Engl J Med,358,1663-71
[19] PageDB,NaidooJ,McArthurHL,,2015,The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy,NPJ Breast Cancer,1,15001-
[20] LalP,SalazarPA,LadanyiM,ChenB,,2003,Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification,J Mol Diagn,5,155-9
[21] DarbyS,McGaleP,CorreaC,TaylorC,ArriagadaR,ClarkeM,,2011,Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials,Lancet,378,1707-16
[22] Geyer JrCE,SamuelJA,WilsonJW,BandosH,ElledgeRM,RobidouxA,-,-,,2014,,[cited 2014 Dec,31,13-02
[23] SwainSM,JeongJH,GeyerCE,CostantinoJP,PajonER,FehrenbacherL,,2010,Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer,N Engl J Med,362,2053-65
[24] ColleoniM,GelberS,GoldhirschA,AebiS,CastiigioneGertschM,PriceKN,,2006,Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node positive breast cancer,International Breast Cancer Study Group Trial 13-93. J Clin Oncol,24,1332-41
[25] HigginsMJ,LiedkePE,GossPE,,2013,Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA,Crit Rev Oncol Hematol,86,23-32
[26] PanK,ChlebowskiRT,,2014,Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer,Clin Breast Cancer,14,147-53
[27] FrancisPA,ReganM,FlemingG,,2014,Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): analysis of the SOFT trial,,,S3-8
[28] BartelinkH,HoriotJC,PoortmansPM,StruikmansH,Van den BogaertW,FourquetA,,2007,Impact of a higher radiation dose on local control and survival in breastconserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial,J Clin Oncol,25,3259-65
[29] RakovitchE,,,,[cited 2014 Dec,13,S5-04
[30] McGaleP,TaylorC,CorreaC,CutterD,DuaneF,EwertzM,,2014,Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials,Lancet,383,2127-35
[31] MukeskMB,BarnettGC,WilkinsonJS,MoodyAM,WilsonC,DorlingL,,2013,Randomized controlled trial of intensitymodulated radiotherapy for early breast cancer. 5-year results confirm superior overall cosmesis,J Clin Oncol,31,4488-95
[32] HaertlPM,PohlF,WeidnerK,GroegerC,KoelblO,DoblerB,,2013,Treatment of left sided breast cancer for a patient with funnel chest: volumetric-modulated arc therapy vs. 3D-CRT and intensity-modulated radiotherapy,Med Dosim,38,1-4
[33] Abo-MadyanY,AzizMH,AlyMM,SchneiderF,SperkE,ClausenS,,2014,Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer,Radiother Oncol,110,471-6
[34] KunklerIH,CanneyP,Van TienhovenG,RussellNS,Oncol (R Coll Radiol,,2008,Elucidating the role of chest wall irradiation in 'intermediaterisk' breast cancer: The MRC/EORTC SUPREMO trial,,20,31-4
[35] HavilandJS,OwenJR,DewarJA,AgrawalRK,BarrettJ,Barrett-LeePJ,,2013,The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10- year follow-up results of two randomised controlled trials,Lancet Oncol,14,1086-94
[36] AgrawalRK,AlhassoA,Barrett-LeePJ,BlissJM,BlissP,BloomfieldD,,2011,First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer,Radiother Oncol,100,93-100
[37] PerezEZ,RomondEH,SumanVJ,NCCTGN9831,,2014,Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31,J Clin Oncol,32,3744-52
[38] SchneeweissA,ChiaS,HickishT,HarveyV,EniuA,HeggR,,2013,Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA),Ann Oncol,24,2278-84
[39] BachmannC,SchmidtS,StaeblerA,FehmT,FendF,SchittenhelmJ,WallwienerD,,2015,CNS metastases in breast cancer patients: prognostic implications of tumor subtype,Med Oncol,32,400-
[40] BaselgaJ,BradburyI,EidtmannH,Di CosimoS,de AzambujaE,AuraC,,2012,Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo-ALTTO): a randomised, open-label, multicentre, phase 3 trial,Lancet,379,633-40
[41] ColemanR,CameronD,DodwellD,BellR,WilsonC,RathboneE,,2014,Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial,Lancet Oncol,15,997-1006
[42] GnantM,MlineritschB,SchippingerW,LuschinEbengreuthG,PöstlbergerS,MenzelC,,2009,Endocrine therapy plus zoledronic acid in premenopausal breast cancer,N Eng J Med,360,679-91
[43] DeCensiA,PuntoniM,GoodwinP,CazzanigaM,GennariA,BonanniB,,2010,Metformin and cancer risk in diabetic patients: a systemic review and metaanalyses,Cancer Prev Res (Phila Pa),3,1451-61
[44] ChlebowskiRT,BlackburnGL,Triple-NegativeBreast-Cancer-May-Reap-Greater-Survival-Benefit-FromNutrition-,,2014,Women-With-,[cited 19 Dec,,-
[45] PaganiO,ReganMM,WalleyBA,ColleoniGF,LangI,GomezHL,,2014,Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer,N Engl J Med,371,107-18
[46] EllisMJ,Llombart-CussacA,FeltlD,DewarJA,JasiówkaM,HewsonN,,2015,Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study,J Clin Oncol,23,3781-7
[47] BaselgaJ,CamponeM,PiccartM,BurrisIII HA,RugoHS,SahmoudT,,2012,Everolimus in Postmenopausal HormoneReceptor-Positive Advanced Breast Cancer,N Engl J Med,366,520-9
[48] VermaS,MilesD,GianniL,KropIE,WelslauM,BaselgaJ,,2012,Trastuzumab emtansine for HER2-positive advanced breast cancer,N Engl J Med,367,1783-91
[49] AndreF,O'ReganR,OzgurogluM,ToiM,XuB,JerusalemG,,2014,Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial,Lancet Oncol,15,580-91
[50] HurvitzSA,AndreF,JiangZ,ShaoZ,NeciosupSP,ManoMS,,2015,-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer:,BOLERO-1,3,-
[51] SchnittSJ,,2010,Will molecular classification replace traditional breast pathology?,Int J Surg Pathol,18,S162-6
[52] GoldhirschA,WoodWC,CoatesAS,GelbrRD,ThurlimannB,SennHJ,,2011,Gallen International expert Consensus on the primary therapy of early breast cancer,2011. Ann Oncol,22,1736-47
[53] ErolesP,BoschA,Pérez-FidalgoJA,LluchA,,2012,Molecular biology in breast cancer: Intrinsic subtypes and signalling pathways,Cancer Treat Rev,38,698-707
[54] PaikS,ShakS,TangG,KimC,BakerJ,CroninM,,2004,A Multigene Assay to Predict Recurrence of TamoxifenTreated, Node-Negative Breast Cancer,N Engl J Med,351,2817-26
[55] CurtisC,ShahSP,ChinSF,TurashviliG,RuedaOM,DunningMJ,,2012,The genomic and transcriptomic architecture of 2000 breast tumors reveal novel subgroups,Nature,486,346-52
[56] MartinM,SeguiMA,AntonA,RuizA,RamosM,AdroverE,,2010,Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer,N Engl J Med,363,2200-10
[57] MamounasEP,BryantJ,LemberskyB,FehrenbacherL,SedlacekSM,FisherB,,2005,Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP B-28,J Clin Oncol,23,3686-96
[58] TolaneyS,BarryW,DangC,YardleyD,MoyB,MarcomP,,2013,Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H)(APT trial) for node-negative, HER2-positive breast cancer (BC,,,-
[59] DisisPL,,,Breast Cancer with High TIL Levels: Skip the Trastuzumab? 2014 Abstract bS1-06,[cited 2014 Dec,24,-
[60] SwainS,KimS,CortesJ,RoJ,SemiglazovV,CamponeM,,2014,Prfinal overall survival (OS) analysis from the cleopatra study of first-line (1L) pertuzumab (PTZ), trastuzumab (T), and docetaxel (D) in patients (pts) with her2-positive metastatic breast cancer (MBC),Ann Oncol,25,4-
[61] HeroldCI,andersCK,,2013,New targets for triple negative breast cancer,Oncology (Williston),27,846-54
[62] ByrskiT,GronwaldJ,HuzarskiT,DentR,ZuziakD,WiśniowskiR,,2011,Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients,,,A4-
[63] SilverDP,RichardsonAL,EklundAC,WangZC,SzallasiZ,LiQ,,2010,Efficacy of neoadjuvant cisplatin in triplenegative breast cancer,J Clin Oncol,28,1145-53
[64] TuttA,RobsonM,GarberJE,DomchekSM,AudehMW,WeitzelJN,,2010,Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial,Lancet,376,235-44
[65] O'Shaughnessy,J , Osborne,C , Pippen,JE , Yoffe,M , Patt,D , Rocha,C,,2011,Iniparib plus chemotherapy in metastatic triple-negative breast cancer,N Engl J Med,364,205-14
[66] ThomasES,GomezHL,LiRK,ChungHC,FeinLE,ChanVF,TaxaneTreatment,,2007,Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline,J Clin Oncol,25,5210-17
[67] DenkertC,MinckwitzGV,BraseJC,Darb-EsfahaniS,GadeS,KronenwettR,,2014,Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy,J Clin Oncol,32,510-
[68] SikovWM,BarryWT,HoadleyKA,PitcherBN,SinghB,TolaneySM,,2014,Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple - negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/ - carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance,,,-
[69] CortesJ,O'ShaughnessyJ,LoeschD,BlumJL,VahdatLT,PetrakovaK,,2011,Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study,Lancet,377,914-23
[70] AebiS,GelberS,AndersonSJ,LangI,RobidouxA,MartinM,,2014,Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial,Lancet Oncol,15,156-63
[71] ,2012,Comprehensive molecular portraits of human breast tumours,Nature,490,61-70
[72] LehmannBD,BauerJA,ChenX,SandersME,ChakravarthyAB,ShyrY,,2011,Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies,J Clin Invest,121,2750-67
[73] LehmannBD,PietenpolJA,,2014,Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes,J Pathol,232,142-50
[74] MasudaH,BaggerlyKA,WangY,ZhangY,GonzalezAnguloAM,Meric-BernstamF,,2013,Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes,Clin Cancer Res,19,5533-40
[75] TurnerN,BiganzoliL,MalorniL,MigliaccioI,MorettiE,PestrinM,,2013,,Adjuvant Chemotherapy: Which Patient? What Regimen. Am Soc Clin Oncol Educ Book,,3-8